Enanta Pharmaceuticals (ENTA) Shares Outstanding (Diluted Average) (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Shares Outstanding (Diluted Average) of $28.9 million for Q1 2026, up 35.68% year-on-year from $21.3 million in Q1 2025, and up 0.5% on a QoQ basis from $28.7 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 9 years of Shares Outstanding (Diluted Average) data on file, last reported at $28.9 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 35.68% year-over-year to $28.9 million; the trailing twelve-month figure through Mar 2026 stood at $28.9 million (up 35.68% YoY), and the FY2025 full-year result was $21336.0, up 0.85% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $28.9 million, up from $28.7 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $28.9 million in Q1 2026 and bottomed at $20603.0 in Q3 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $21.1 million (2023), against an average of $17.0 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) climbed 0.6%; it then jumped 35.68% in 2026.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $20.8 million in 2022, then gained by 1.31% to $21.1 million in 2023, then rose by 0.71% to $21.2 million in 2024, then soared by 35.36% to $28.7 million in 2025, then advanced by 0.5% to $28.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $28.9 million (Q1 2026), $28.7 million (Q4 2025), and $21336.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 28.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.89 Mn |
| Dec 31, 2025 | 28.75 Mn |
| Sep 30, 2025 | 21,336.00 |
| Jun 30, 2025 | 21.38 Mn |
| Mar 31, 2025 | 21.30 Mn |
| Dec 31, 2024 | 21.24 Mn |
| Sep 30, 2024 | 21,157.00 |
| Jun 30, 2024 | 21.18 Mn |
| Mar 31, 2024 | 21.13 Mn |
| Dec 31, 2023 | 21.09 Mn |
| Sep 30, 2023 | 20,969.00 |
| Jun 30, 2023 | 21.05 Mn |
| Mar 31, 2023 | 20.88 Mn |
| Dec 31, 2022 | 20.82 Mn |
| Sep 30, 2022 | 20,603.00 |
| Jun 30, 2022 | 20.55 Mn |
| Mar 31, 2022 | 20.47 Mn |
| Dec 31, 2021 | 20.39 Mn |
| Sep 30, 2021 | 20,171.00 |
| Sep 30, 2020 | 19,940.00 |
| Jun 30, 2013 | 17.82 Mn |
| Mar 31, 2013 | 3.08 Mn |
| Jun 30, 2012 | 1.12 Mn |
| Mar 31, 2012 | 2.38 Mn |